A Real-World Characterization of US Patients with "Moderate-to-Severe" Systemic Lupus Erythematosus.

被引：0
|
作者：
Strand, Vibeke
Johnson, Jennifer [1 ]
Vandeloo, Carl [2 ]
Galateanu, Catrinel [2 ]
Lobosco, Steve [1 ]
机构：
[1] Adelphi Real World Ltd, Macclesfield, Cheshire, England
[2] UCB Pharma, Brussels, Belgium
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1077
引用
收藏
页码：S475 / S475
页数：1
相关论文
共 50 条
  • [1] A REAL-WORLD CHARACTERIZATION OF PATIENTS WITH "MODERATE-TO-SEVERE" SYSTEMIC LUPUS ERYTHEMATOSUS
    Strand, V
    Johnson, J.
    Vandeloo, C.
    Galateanu, C.
    Lobosco, S.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A522 - A522
  • [2] A "REAL-WORLD" CHARACTERIZATION OF MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS
    Strand, V.
    Johnson, J.
    Vandeloo, C.
    Galateanu, C.
    Lobosco, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 626 - 627
  • [3] Blisibimod, an Inhibitor of B Cell Activating Factor, in Patients with Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie, Richard A.
    Scheinberg, Morton A.
    Leon, Gustavo
    Ramiterre, Edgar B.
    Thomas, Matthew
    Martin, Renee S.
    Petri, Michelle A.
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (12): : 4169 - 4169
  • [4] TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE SEVERITY
    Strand, V.
    Johnson, J.
    Vandeloo, C.
    Galateanu, C.
    Lobosco, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1171 - 1171
  • [5] Exploratory Analysis of Pharmacokinetic Effects of Atacicept in Patients with Moderate to Severe Systemic Lupus Erythematosus.
    Wofsy, David
    Gordon, Caroline
    Li, Yong
    Wax, Stephen D.
    Isenberg, David
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1240 - S1241
  • [6] Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States
    Wu, Sandra Sze-jung
    Perry, Allison
    Tkacz, Joseph
    Bryant, Gary
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (09): : 1010 - 1020
  • [7] Real-world disease burden in US adults with moderate-to-severe atopic dermatitis eligible for treatment with systemic immunosuppressants
    Armstrong, April
    Moon, Rachel
    Bell, David
    Blackburn, Stuart
    Wei, Wenhui
    Chao, Jingdong
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB215 - AB215
  • [8] Characterization of prolactine in the serum of patients with systemic lupus erythematosus.
    Cruz, J
    Avina-Zubieta, A
    de la Escalera, GM
    Clapp, C
    Lavalle, C
    [J]. ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S101 - S101
  • [9] Evaluation of the Efficacy and Safety of Anifrolumab in Moderate-to-Severe Systemic Lupus Erythematosus
    Cingireddy, Ananya Reddy
    Ramini, Navya
    Cingireddy, Anirudh Reddy
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [10] Moderate and severe neutropenia in patients with systemic lupus erythematosus
    Martinez-Banos, D.
    Crispin, J. C.
    Lazo-Langner, A.
    Sanchez-Guerrero, J.
    [J]. RHEUMATOLOGY, 2006, 45 (08) : 994 - 998
12345